• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLPT alert in real time by email
    For Immediate Release:
    November 14, 2024

    The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency.

    “Clinical advancements in the field of gene therapy continue to lead to the discovery and availability of innovative treatment options for rare diseases that are otherwise difficult to manage,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “Today’s approval underscores our commitment to help make safe and effective treatments available for patients in need.” 

    Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters, which are chemical messengers that allow cells in the body’s nervous system to communicate with each other. Affected individuals may experience symptoms such as delays in gross motor function (head control, sitting, standing, and walking), hypotonia (weak muscle tone), and developmental and cognitive delays. 

    “AADC deficiency can cause a range of debilitating symptoms, including life-threatening complications,” said Nicole Verdun, M.D., director of the Office of Therapeutic Products in CBER. “Today’s approval represents important progress in the advancement and availability of safe and effective treatments for debilitating genetic disorders.” 

    Kebilidi is administered via four infusions in one surgical session into a large structure in the brain involved in motor control. Kebilidi should be administered in a medical center that specializes in pediatric stereotactic neurosurgery — a technique that uses imaging and special equipment to deliver therapies to specific areas in the brain. After infusion of Kebilidi, treatment results in the expression of AADC and subsequent increase in the production of dopamine, a critical neurotransmitter in the brain associated with movement, attention, learning and memory.

    The safety and effectiveness of Kebilidi were demonstrated in an open-label, single-arm clinical study in 13 pediatric patients with confirmed diagnosis of AADC deficiency. At the start of the study, all patients had no gross motor function (the most severe presentation of AADC deficiency) and decreased AADC activity in the plasma. Patients treated with Kebilidi were compared to untreated patients (natural history). Motor milestone assessments were completed for 12 of the 13 patients at week 48 after receiving the treatment. The efficacy of Kebilidi was demonstrated based on gross motor function improvement in 8 of 12 treated patients, which has not been reported in untreated patients with the severe presentation of AADC deficiency. 

    The most common adverse reactions of Kebilidi are dyskinesia (involuntary muscle movements), fever, low blood pressure, anemia (low red blood cell count), increased saliva production, insomnia, low levels of potassium, phosphate, and/or magnesium, and procedural complications such as respiratory and cardiac arrest. It is also contraindicated in patients who have not achieved skull maturity assessed by neuroimaging.

    Kebilidi was approved using the Accelerated Approval pathway. Accelerated approval allows the FDA to approve certain products for serious or life-threatening conditions based on evidence of a product’s effect on a surrogate endpoint or an intermediate clinical endpoint that is reasonably likely to predict clinical benefit. In the FDA’s evaluation of Kebilidi for accelerated approval, evidence of effectiveness is based on early improvements in gross motor function measured at 48 weeks after treatment. Continued approval for this indication may be contingent upon verification and description of clinical benefit of the product, such as the durability of the improvements, in a confirmatory clinical trial. A confirmatory trial is ongoing to verify Kebilidi’s clinical benefit.

    The application received Priority Review and Orphan Drug designation, and was granted a rare pediatric disease priority review voucher by the FDA. 

    The FDA also authorized the SmartFlow Neuro Cannula, an infusion tube inserted into a target in the brain (parenchymal tissue), to deliver Kebilidi. The SmartFlow Neuro Cannula is currently the only FDA authorized device indicated for use to administer Kebilidi. The FDA granted authorization of the SmartFlow Neuro Cannula to ClearPoint Neuro, Inc.

    The FDA granted approval of Kebilidi to PTC Therapeutics, Inc.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    Carly (Kempler) Pflaum
    240-672-8872
    Consumer:
    888-INFO-FDA

    Get the next $CLPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLPT
    $PTCT

    CompanyDatePrice TargetRatingAnalyst
    PTC Therapeutics Inc.
    $PTCT
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    PTC Therapeutics Inc.
    $PTCT
    5/7/2025$40.00Sell → Neutral
    Citigroup
    PTC Therapeutics Inc.
    $PTCT
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    PTC Therapeutics Inc.
    $PTCT
    3/7/2025$55.00Sector Perform
    Scotiabank
    PTC Therapeutics Inc.
    $PTCT
    12/13/2024$45.00 → $67.00Equal-Weight → Overweight
    Morgan Stanley
    PTC Therapeutics Inc.
    $PTCT
    12/3/2024$39.00 → $63.00Sector Perform → Outperform
    RBC Capital Mkts
    PTC Therapeutics Inc.
    $PTCT
    10/10/2024Mkt Perform
    Raymond James
    PTC Therapeutics Inc.
    $PTCT
    9/4/2024$44.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLPT
    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WARREN, N.J., May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on April 

      5/1/25 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLPT
    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLPT
    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      12/14/23 4:38:32 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLPT
    $PTCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

      SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein

      7/17/23 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00

      5/9/25 8:40:13 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00

      5/7/25 8:34:42 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously

      3/11/25 7:43:05 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLPT
    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      11/14/24 5:22:11 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $136,656 worth of shares (2,804 units at $48.74), decreasing direct ownership by 1% to 273,234 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/24/25 5:20:05 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $42,114 worth of shares (897 units at $46.95), decreasing direct ownership by 1% to 75,997 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/4/25 5:20:04 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fletcher R John was granted 486 shares, increasing direct ownership by 0.52% to 94,398 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:23:54 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    $PTCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by PTC Therapeutics Inc.

      10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:34:25 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:03:36 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/5/25 7:55:12 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLPT
    $PTCT
    Financials

    Live finance-specific insights

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

      WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investors

      4/17/25 8:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care